Immunocore presents Phase 1 data of brenetafusp, an ImmTAC bispecific targeting PRAME, in patients with ovarian cancer Brenetafusp is clinically…
- Clinically meaningful objective response rate (ORR) of 63.3-76.7% observed with belrestotug + dostarlimab combinations, with confirmed ORR (cORR) at…
LUND, SWEDEN / ACCESSWIRE / September 14, 2024 / Cantargia (STO:CANTA) Cantargia (Cantargia AB; Nasdaq Stockholm:CANTA) today presented data from…
Preliminary immunogenicity results demonstrate induction of cancer antigen-specific T-cell responses in 77% of evaluable patients following CVGBM monotherapy84% of immune…
SEATTLE WA and LUND, SWEDEN / ACCESSWIRE / September 13, 2024 / Aptevo Therapeutics ("Aptevo") (NASDAQ:APVO) and Alligator Bioscience AB…
AMSTERDAM, Sept. 13, 2024 (GLOBE NEWSWIRE) -- (NASDAQ: RENB) RenovaroCube (Cube, the Company), a leading AI-driven innovator using multi-omics technology…
BOSTON, Sept. 13, 2024 (GLOBE NEWSWIRE) -- Elicio Therapeutics, Inc. (Nasdaq: ELTX, “Elicio Therapeutics” or “Elicio”), a clinical-stage biotechnology company developing…
FORT LEE, N.J., Sept. 12, 2024 (GLOBE NEWSWIRE) -- Elevar Therapeutics, Inc., a majority-owned subsidiary of HLB Co., Ltd., today…
Vironexis’s off-the-shelf, single-dose gene therapies aim to deliver cancer treatments that are safer, more effective and long-lasting, and more easily…
Soquelitinib is a potential first-in-class ITK inhibitor with broad potential in cancer and immune diseases There are currently no fully…